In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
After finishing at $24.78 in the prior trading day, Bright Minds Biosciences Inc (NASDAQ: DRUG) closed at $23.27, down -6.09%. In other words, the price has decreased by -$6.09 from its previous closing price. On the day, 0.63 million shares were traded. DRUG stock price reached its highest trading level at $25.61 during the session, while it also had its lowest trading level at $23.175.
Ratios:
Our goal is to gain a better understanding of DRUG by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 88.27 and its Current Ratio is at 88.27. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On May 07, 2025, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $80.
On January 23, 2025, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $93.Piper Sandler initiated its Overweight rating on January 23, 2025, with a $93 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 04 ’24 when Cormorant Asset Management, LP bought 184,331 shares for $21.70 per share. The transaction valued at 3,999,983 led to the insider holds 1,059,331 shares of the business.
Cormorant Asset Management, LP bought 372,591 shares of DRUG for $2,061,574 on Oct 15 ’24. The 10% Owner now owns 825,000 shares after completing the transaction at $5.53 per share. On Oct 16 ’24, another insider, Cormorant Asset Management, LP, who serves as the 10% Owner of the company, bought 50,000 shares for $23.46 each. As a result, the insider paid 1,172,813 and bolstered with 875,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DRUG now has a Market Capitalization of 172774640 and an Enterprise Value of 109313648.
Stock Price History:
The Beta on a monthly basis for DRUG is -5.99, which has changed by 21.161905 over the last 52 weeks, in comparison to a change of 0.12748289 over the same period for the S&P500. Over the past 52 weeks, DRUG has reached a high of $79.02, while it has fallen to a 52-week low of $0.93. The 50-Day Moving Average of the stock is -21.70%, while the 200-Day Moving Average is calculated to be -26.12%.
Shares Statistics:
The stock has traded on average 27.59K shares per day over the past 3-months and 84600 shares per day over the last 10 days, according to various share statistics. A total of 7.08M shares are outstanding, with a floating share count of 4.93M. Insiders hold about 30.37% of the company’s shares, while institutions hold 57.64% stake in the company. Shares short for DRUG as of 1749772800 were 86404 with a Short Ratio of 3.13, compared to 1747267200 on 80327. Therefore, it implies a Short% of Shares Outstanding of 86404 and a Short% of Float of 1.79.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
